Andrew Huberman· PhD
Buckle up for pharma developing new antidepressants based on psychedelics but that lack hallucinogenic properties for instance.
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Buckle up for pharma developing new antidepressants based on psychedelics but that lack hallucinogenic properties for instance.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
There are several papers published recently in great journals like nature and science, et cetera, where there are scientists who are removing the hallucinogenic components of these drugs and finding that they still have the antidepressant effects.
For instance, we discuss how a number of laboratories and clinics are modifying psychedelics to remove some of their hallucinogenic properties while maintaining some of their antidepressant or anti trauma properties.
we have laboratories who are trying to tease apart the activation of receptors independent of all that subjective experience in order to, essentially, treat the same conditions.
modifying psychedelics so that they have potential therapeutic application for the treatment of depression but zero hallucinogenic properties.
there's a bit of a movement within the scientific community that studies psychedelics to develop drugs that can, essentially, cure or alleviate many of the symptoms of depression or trauma that are built off our understanding of how psychedelics like psilocybin and here I'll throw MDMA in there, although classically not a psychedelic, it gets lumped in.